BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $120 from $112 and keeps an Outperform rating on the shares. The myelofibrosis, MF, anemia key opinion leader event gives a comprehensive look at the treatment landscape and how Disc Medicine remains early but differentiated, the analyst tells investors in a research note. Following the event and the firm’s recent Phase 3 INDEPENDENCE luspaterecpt data preview, BMO is more encouraged by DISC-0974’s value and its positioning in MF anemia as DISC-0974 has shown potential to be used as a monotherapy, the firm added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRON:
- Disc Medicine’s Promising Position in MF Anemia Treatment: Buy Rating Affirmed by Evan Seigerman
- Promising Outlook for Disc Medicine’s DISC-0974 in Anemia Treatment Justifies Buy Rating
- Disc Medicine Reports Strong Q1 2025 Progress
- Buy Rating for Disc Medicine Driven by Promising Bitopertin Prospects and Strategic Advancements
- Promising Developments at Disc Medicine: NDA Filing and Phase III Trial for Bitopertin in EPP